| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 65,927 | 64,025 | ||
| Marketable securities | 101,667 | 141,106 | ||
| Accounts receivable | 3,922 | 7,999 | ||
| Prepaid expenses and other current assets | 10,597 | 18,500 | ||
| Total current assets | 182,113 | 231,630 | ||
| Property and equipment, net | 13,346 | 14,981 | ||
| Operating lease right-of-use assets | 13,341 | 14,836 | ||
| Other non-current assets | 0 | 50 | ||
| Restricted cash | 858 | 858 | ||
| Total assets | 209,658 | 262,355 | ||
| Accounts payable | 7,034 | 4,308 | ||
| Accrued compensation | 13,248 | 11,764 | ||
| Deferred revenue - current | 8,977 | 11,964 | ||
| Operating lease liability - current | 7,960 | 8,057 | ||
| Accrued expenses and other current liabilities | 34,676 | 38,153 | ||
| Total current liabilities | 71,895 | 74,246 | ||
| Deferred revenue - non-current | 3,758 | 6,906 | ||
| Operating lease liability - non-current | 9,701 | 11,536 | ||
| Deferred royalty obligation related to the sale of future royalties | 209,878 | 200,084 | ||
| Other non-current liabilities | 1,694 | 1,694 | ||
| Total liabilities | 296,926 | 294,466 | ||
| Common stock, 0.001 par value - 300,000,000 shares authorized as of september 30, 2025 and december 31, 2024 85,101,749 and 82,526,430 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 85 | 85 | ||
| Additional paid-in-capital | 843,807 | 842,153 | ||
| Accumulated other comprehensive income | 33 | -13 | ||
| Accumulated deficit | -931,193 | -874,336 | ||
| Total stockholders' (deficit) equity | -87,268 | -32,111 | ||
| Total liabilities and stockholders' (deficit) equity | 209,658 | 262,355 | ||
SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC. (STRO)